Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Losartan
Drug ID BADD_D01322
Description Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.[L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.[L7423] When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide].[L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored.[L7423] Losartan was granted FDA approval on 14 April 1995.[L7423]
Indications and Usage May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Marketing Status Prescription; Discontinued
ATC Code C09CA01
DrugBank ID DB00678
KEGG ID D08146
MeSH ID D019808
PubChem ID 3961
TTD Drug ID D0DD0K
NDC Product Code Not Available
Synonyms Losartan | 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol | DuP-753 | DuP 753 | DuP753 | MK-954 | MK 954 | MK954 | Cozaar | Losartan Potassium | Potassium, Losartan | Losartan Monopotassium Salt | Monopotassium Salt, Losartan | Salt, Losartan Monopotassium
Chemical Information
Molecular Formula C22H23ClN6O
CAS Registry Number 114798-26-4
SMILES CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Capillary fragility increasedInterleukin-1 alphaP01583T1634026156105
Capillary fragility increasedInterleukin-10P29456Not Available26156105
Capillary fragility increasedC-C motif chemokine 2P14844Not Available26156105
Metabolic disorderCytochrome P450 2C9P11712T192449663807; 11434505; 9825828
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nervousness19.06.02.0030.000121%Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neutropenia01.02.03.004--Not Available
Neutrophil count decreased13.01.06.010--
Nightmare19.02.03.003--Not Available
Nocturia20.02.03.0010.000049%Not Available
Normochromic normocytic anaemia01.03.02.0050.000049%Not Available
Obesity14.03.02.0090.000049%
Ocular hyperaemia06.04.05.004--Not Available
Odynophagia07.05.03.0010.000097%Not Available
Oedema08.01.07.006; 14.05.06.010--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oesophageal carcinoma16.13.06.001; 07.21.06.0010.000013%Not Available
Oligohydramnios18.05.01.0010.000243%Not Available
Oliguria20.01.03.0040.000073%Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.0200.000073%Not Available
Osteoarthritis15.01.04.001--Not Available
Osteomyelitis15.02.05.001; 11.01.01.0010.000073%
Oxygen saturation decreased13.02.01.004--Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pain of skin23.03.03.0030.000073%
Pallor23.03.03.031; 08.01.03.032; 24.03.04.001--Not Available
Palpitations02.01.02.0030.000534%
Pancreatic carcinoma16.13.10.001; 07.21.09.0020.000025%Not Available
Pancreatitis07.18.01.001--
Pancreatitis acute07.18.01.002--Not Available
Pancytopenia01.03.03.003--Not Available
Panic attack19.06.04.001--Not Available
Panic disorder19.06.04.002--Not Available
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 19 Pages